ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-K: FY2025 Revenue: USD 6.202 K

Revenue: As of FY2025, the actual value is USD 6.202 K.

EPS: As of FY2025, the actual value is USD -16.38.

EBIT: As of FY2025, the actual value is USD -10.82 M.

Aspire Biopharma Holdings, Inc. operates as a single reportable segment, with its CEO focusing on operating expenses, cash, and cash equivalents for overall performance review and resource allocation.

Revenue

• Net Revenue for 2025 was $6,202, compared to $0 in 2024, as the company commenced earning revenue from nutraceutical product sales in Q3 2025.

Operational Metrics

• Cost of Revenue: Cost of revenue was $6,318 in 2025, up from $0 in 2024.
• Gross Margin: The company reported a gross margin of - $116 in 2025, compared to $0 in 2024.
• Operating Expenses:
  • General and Administrative Expenses increased by $16,697,011 to $17,637,432 in 2025, from $940,421 in 2024.
  • Research and Development Expenses rose by $779,558 to $923,914 in 2025, from $144,356 in 2024.
  • Sales and Marketing Expenses increased by $663,735 to $789,829 in 2025, from $126,094 in 2024.
• Loss from Operations: Loss from operations was - $19,351,291 in 2025, significantly higher than - $1,210,871 in 2024.
• Other Income (Expenses):
  • Interest Expense was - $8,531,275 in 2025, an increase of - $8,433,287 compared to - $97,988 in 2024.
  • Change in Fair Value of Liabilities was $3,860,889 in 2025, compared to $0 in 2024.
  • Initial Recognition of Forward Purchase Liability was - $95,062 in 2025, compared to $0 in 2024.
  • Loss on Extinguishment of Debt was - $364,109 in 2025, compared to $0 in 2024.
  • Other Expense, Net was - $5,129,557 in 2025, compared to - $97,988 in 2024.
• Net Loss: Net loss for 2025 was - $24,480,848, compared to - $1,309,872 in 2024.

Cash Flow

• Net Cash Used in Operating Activities was - $4,923,488 in 2025, compared to - $265,186 in 2024.
• Net Cash Provided by Financing Activities was $5,923,759 in 2025, compared to $257,645 in 2024.

Liquidity and Capital Resources

• As of December 31, 2025, the accumulated deficit was $27,258,081 and the working capital deficit was $6,280,667.
• Cash on hand as of December 31, 2025, was $1,003,904.

Unique Metrics / Operational Highlights

• Aspirin Product Development: A clinical trial for sublingual aspirin was successfully completed in July 2025, demonstrating positive results for faster bioavailability and anti-coagulant properties, with plans to submit a 505(b)(2) NDA to the FDA.
• Caffeine Products: Sales of “Buzz Bomb” caffeine products began in Q3 2025, with new marketing and labeling for 2,000,000 units starting on January 15, 2026.
• Capital Raising: In 2025, the company received approximately $265,827 from a Reverse Recapitalization, $3,000,000 from convertible notes, and $2,661,459 from a Securities Purchase Agreement. In February 2026, it received approximately $6,777,206 from the first tranche of convertible preferred stock purchases.
• Equity Line of Credit (ELOC): A Second ELOC Agreement was entered in November 2025, allowing the sale of up to $100,000,000 in common stock over 24 months.

Outlook / Guidance

Aspire Biopharma Holdings, Inc. plans to submit its FDA 505(b)(2) approval request for its prescription strength high-dose aspirin product in late 2026. The company intends to conduct an additional clinical trial for this product starting around June 2026, following a positive FDA response to its pre-IND request. General and administrative, research and development, and sales and marketing expenses are expected to increase in future periods due to business growth and public company status.